Angels Arcusa Lanza

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Miguel Martín, Frankie A. Holmes, Bent Ejlertsen et al. · The Lancet Oncology · 2017 · 578 citations

5-Year Analysis, Breast Oncology, Oncology +10

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-II study

Emilio Alba, Lourdes Calvo, Joan Albanell et al. · Annals of Oncology · 2012 · 222 citations · Full text

Breast Oncology, Oncology, Phase-ii Study +5

Leiomyomas in patients receiving Tamoxifen.

Livio Leo, Angels Arcusa Lanza, Re A et al. · PubMed · 1994 · 21 citations

Uterine Leiomyomas, Surgical Oncology, Breast Oncology +13

Chemotherapy (CT) versus hormone therapy (HT) as neoadjuvant treatment in luminal breast cancer: A multicenter, randomized phase II study (GEICAM/2006-03).

Emilio Alba, Lourdes Calvo, Joan Albanell et al. · Journal of Clinical Oncology · 2010 · 14 citations

Surgical Oncology, Breast Oncology, Luminal Subgroup +20